Lineage-specific Modulation of Interleukin 4 Signaling by Interferon Regulatory Factor 4

By Sanjay Gupta, Man Jiang, Alissa Anthony, and Alessandra B. Pernis

From the Department of Medicine, Columbia University, New York, New York 10032

Summary

Interleukin (IL)-4 is an immunoregulatory cytokine that exerts distinct biological activities on different cell types. Our studies indicate that interferon regulatory factor (IRF)-4 is both a target and a modulator of the IL-4 signaling cascade. IRF-4 expression is strongly upregulated upon costimulation of B cells with CD40 and IL-4. Furthermore, we find that IRF-4 can interact with signal transducer and activator of transcription (Stat)6 and drive the expression of IL-4-inducible genes. The transactivating ability of IRF-4 is blocked by the repressor factor BCL-6. Since expression of IRF-4 is mostly confined to lymphoid cells, these data provide a potential mechanism by which IL-4-inducible genes can be regulated in a lineage-specific manner.

Key words: CD40 • interleukin 4 • signal transducer and activator of transcription 6 • BCL-6 • interferon regulatory factor 4

Interleukin (IL)-4 is an immunoregulatory cytokine that exerts a wide variety of effects on many different cell types (1–3). IL-4 plays a central role in the regulation of immune responses by promoting the differentiation of T helper cells toward the Th2 subset. Furthermore, IL-4 synergizes with stimuli provided by CD40 to drive B cell activation, proliferation, and differentiation, thus strongly enhancing humoral immunity (4).

IL-4 mediates its biological actions by activating a signaling cascade, which follows the paradigm originally described for the IFN signaling pathway (5–7). Binding of IL-4 to its receptor leads to the activation, via Janus kinases (JAKs), of a latent cytoplasmic protein, signal transducer and activator of transcription (STAT)6 (Stat6) (8). Tyrosine phosphorylation of Stat6 allows it to homodimerize and rapidly translocate into the nucleus where it modulates gene transcription by binding to distinct cis-elements termed gamma-activated sites (GAS). Although studies in Stat6-deficient mice have demonstrated that Stat6 plays a key role in IL-4 signaling (9–11), additional factors are likely to participate in this cascade. Indeed, the rapidity of Stat6 activation in response to IL-4 cannot solely explain the inducibility of IL-4 target genes like CD23, whose activation displays a delayed kinetics (12). Moreover, tyrosine phosphorylation of Stat6 in response to IL-4 has been detected in a wide variety of cells (13–17). Thus, the differential gene expression triggered by IL-4 in diverse cell types must involve the presence and/or recruitment of additional, possibly cell type-specific, cofactors.

Consistent with the requirements for additional protein-protein interactions in the regulation of IL-4-responsive genes, the activity of Stat6 can be downregulated by B cell lymphomas 6 (BCL-6). BCL-6 is a Krüppel zinc finger transcriptional repressor that is highly expressed in germinal center B cells and is frequently altered in non-Hodgkin lymphoma (18–21). BCL-6 has been shown to bind to the GAS element in the CD23b promoter and repress Stat6-mediated promoter function (22). Mice deficient in BCL-6 display loss of germinal centers as well as an inflammatory disease characterized by exaggerated Th2 responses including elevated levels of serum IgG1 and IgE, supporting a role for BCL-6 as a repressor of the IL-4 signaling pathway in vivo (22, 23). However, generation of mice deficient in both BCL-6 and Stat6 failed to abrogate the Th2 inflammatory disease, suggesting that not all of the defects present in the BCL-6-deficient mice can be simply ascribed to its repression of Stat6 function (24).

Studies of the IFN signaling pathway have demonstrated that another family of transcription factors, the IFN regulatory factor (IRF) family, is both a target and a modulator of this cytokine signaling cascade (25, 26). Genetic studies have demonstrated a role for IRF proteins in the proliferation, differentiation, and apoptosis of a variety of immune effector cells, suggesting the involvement of IRFs in pathways in addition to those triggered by the IFNs (27, 28). In particular, lack of one of these newly cloned IRF proteins...
IRF-4 (also termed Pip, LRIF, ICSAT, or MUM1 [29-32]), results in striking defects in the function of mature B and T cells (33). Consistent with these results, expression of both murine and human IRF-4 is mostly confined to the lymphoid compartment and is induced in response to mitogenic stimuli (31, 32, 34). Functional studies have shown that IRF-4 is involved in the transactivation of both the κ and λ Ig light chain enhancers as well as the CD20 promoter (29, 35-37). However, the effect of IRF-4 on these enhancers is unlikely to explain the profound immunologic impairments demonstrated by the gene targeting studies. Additional IRF-4 targets and the physiological stimuli that activate IRF-4 are unknown.

We are interested in understanding the downstream effects of the IL-4 signaling pathways in B cells as well as the mechanisms underlying the cross-talk between the CD40 and IL-4 signaling pathways. We focused our attention on the regulation of the CD23 gene (38-41). CD23 induction in response to IL-4 and CD40 occurs with delayed kinetics, and displays a synergistic response when the two stimuli are combined (12, 42, 43). In humans, CD23 exists as two alternatively spliced isoforms, termed CD23a and CD23b, which differ only in the intracytoplasmic domain. Expression of CD23a and CD23b is controlled by two separate promoters (44). IL-4 inducibility of the CD23b isoform has been functionally mapped to a Stat6 binding element within the CD23b promoter termed the CD23b GAS (13, 45). We have found that the recently cloned IRF-4 can physically interact with Stat6 and act as a transactivator of the CD23b GAS. Presence of BCL-6 blocks the transactivating potential of IRF-4. While BCL-6 is known to be downregulated in a cell type-specific manner. Furthermore, the ability of CD40 and IL-4 to target the expression of multiple components of this nucleoprotein complex may underlie the synergistic interaction between these two pathways.

Materials and Methods

Cell Lines and Cultures. The human B cell lines Ramos (obtained from Dr. Seth Lederman, Columbia University) and BL-41 (obtained from Dr. R. Riccardo Dalla-Favera, Columbia University) are EBV-negative Burkitt's lymphoma. JY (obtained from Dr. R. Riccardo Dalla-Favera) is an EBV-transformed lymphoblastoid B cell line. U937 (obtained from Dr. Kathryne Calame, Columbia University) is a monocytic cell line. All cells were grown in IMDM supplemented with 10% fetal calf serum (Atlanta Biologicals, Inc.).

Ramos B cells (10-20 x 10^6) were stimulated with 0.1 μg/ml of either anti-CD40 or an isotype-matched control Ab in a final volume of 10 ml at 37°C for 24 h. IL-4 treatment (100 U/ml; PeproTech) was carried out simultaneously in separate plates in a final volume of 10 ml. Tonsillar mononuclear cells were obtained from surgical specimens after routine tonsillectomies and were isolated as described previously (47).

Abs. The rabbit polyclonal antiserum against IRF-4 used in electrophoretic mobility shift assay (EMSA) experiments was a gift of Dr. Hira, Tokyo University, Tokyo, Japan (32). We subsequently generated our own rabbit polyclonal anti-IRF-4 antiserum using a similar glutathione S-transferase (GST)–IRF-4 (nucleotides 441-924) fusion protein as the immunogen (Babco). As previously indicated, this GST fusion protein contains a portion of the IRF-4 protein that is specific to IRF-4 and thus avoids cross-reactivity with other IRFs (32). This antiserum was used for immunoprecipitations and immunoblot analyses. Blots were also reprobed with a commercially available anti-IRF-4 antiserum (Santa Cruz Biotechnology), which gave identical results. Rabbit polyclonal antiserum against human Stat6, Stat3, p65, IRF-2, IFN consensus sequence binding protein (ICSBP), or BCL-6, were purchased from Santa Cruz Biotechnology, Inc. The hybridomas secreting the anti-CD40 mAb G28-5 (IgG1) or an isotype-matched control mAb were obtained from American Type Culture Collection.

DNA Constructs. Full-length human IRF-4 cDNA cloned into pbLuescript vector (pBKS-S-myc-IRF-4) was a gift of Dr. R. Riccardo Dalla-Favera (30). The IRF-4 expression plasmid pCPEP-IRF-4 was constructed by cloning the entire coding region of the IRF-4 cDNA into the NotI and XhoI sites of the mammalian expression vector pCPE4 (Invitrogen). For construction of the GST–IRF-4 expression plasmid, the entire coding region of the IRF-4 cDNA was cloned, in frame, into the filled EcoRI site of pGEX-3X vector (Amersham Pharmacia Biotech). The in frame junctions in the GST–IRF-4 fusion construct were confirmed by DNA sequencing in an automated cycle sequencer (Perkin Elmer). The full-length human BCL-6 cDNA cloned into pMT2T mammalian expression vector was a gift of Dr. R. Riccardo Dalla-Favera (19).

The CD23a cDNA was a gift of Dr. Kikutani, Osaka University, Osaka, Japan (44) and Dr. D. Wang, Harvard University, Boston, MA (48). To generate an antisense riboprobe of CD23a/b, a 600-bp 5′-EcoRI-HindIII-3′ fragment from the 5′ end of CD23a cDNA was cloned in opposite orientation, into the HindIII and EcoRI sites of pgEM1 in vitro transcription vector (Promega). Transcription of the antisense RNA was driven by SP6 RNA polymerase promoter.

To prepare the CD23a GAS firefly luciferase reporter construct, a trimer of the CD23b GAS element was synthesized with flanking BamHI sites (GBBCO BR L) and then cloned into the BamHI site (immediately upstream of minimal TK promoter) of the TK 200 luciferase reporter vector (a gift of Dr. Kathryn Calame). The CD23b promoter firefly luciferase reporter construct in the pGL3-enhancer vector (Promega) is a gift of Dr. Seth Lederman. The pRL-TK reporter plasmid encoding renilla luciferase to determine the transfection efficiency was purchased from Promega.

DNA Binding Assays and Cell Extracts. The preparation and employment of DNA oligonucleotide probes for EMSAs have been described previously (49) with the following modifications: 2% poly(dI-dC) concentration (1 μg/ml) reaction) was used in the binding buffer. The CD23b GAS oligonucleotides used in these studies were as follows: CD23b GAS wild-type (wt), 5′-gatcGGGTGAATTTCTAAGAAAGGGAC-3′; CD23b GAS M1, 5′-gatcGGGTGAATTTCTAAGGGGAC-3′; CD23b GAS M2, 5′-gatcGGGTGAATTTCTAAGGGGAC-3′; and CD23b GAS M3, 5′-gatcGGGTGAATTTCTAAGGGGAC-3′. The oligonucleotide competition and Ab interference assays were performed as described previously (49). Nuclear and whole cell extracts (WCEs) were prepared as described previously (49, 50). Immunoprecipitations, Western blot analysis, and UV cross-linking assays. Cell extracts were immunoprecipitated with an anti-IRF-4, anti-BCL-6, or anti-Stat6 antiserum as described previ-
ously (49). The immunoprecipitates were resolved by 7% SDS-PAGE. The gel was transferred to a nitrocellulose membrane, and then immunoblotted with a Stat6, BCL-6, or IRF-4 Ab. The bands were visualized by ECL (Amersham Pharmacia Biotech). UV cross-linking was performed as described previously (49).

**GST Pull-down Assays.** GST fusion proteins were expressed in E. coli DH5α and affinity-purified on glutathione (GSH)-agarose beads (Sigma Chemical Co.), as described previously (51). The concentration of each fusion protein was determined by SDS-PAGE/Coomassie staining. For pull-down assays, lysates (~2 mg of total cell proteins) from control or stimulated Ramos or JY cells were incubated with ~100 μg of GST alone or GST–IRF-4 fusion protein immobilized onto GSH-agarose beads in 400 μl of 1× lysis buffer (50 mM Tris HCl, pH 8.0, 150 mM NaCl, 0.1 mM EDTA, 10% glycerol, 1 mM dithiothreitol, 1 mM Na₂VO₃, 1 mM PMSF, 1 μg/ml leupeptin, 3 μg/ml aprotinin) for 4 h at 4°C with constant agitation. The complexes were extensively washed with 1× lysis buffer (containing 0.5% NP-40). The bound proteins were eluted from the beads by boiling them in SDS-PAGE sample buffer, fractionated on a 7% SDS-polyacrylamide gel, and then blotted onto a nitrocellulose membrane. The blot was probed with either a Stat6, Stat3, or BCL-6 Ab.

**Northern Analysis and RNase Protection Assays.** Total RNA was extracted by using the R N A-STAT60 kit (TelTest, Inc.). Northern blot analysis was performed with 10 μg of total RNA according to standard protocols. The blot was probed with either a human IRF-4 cDNA, a BCL-6 cDNA, or a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA radiolabeled by the DNA Labeling Kit (Amersham Pharmacia Biotech). RNase protection analysis was performed as described previously (52). 10 μg of total RNA was hybridized simultaneously to an antisense riboprobe of CD23a/b as well as of β-actin (Ambion) transcribed using [α-32P]UTP. The annealed products were digested with ribonuclease T2 (GIBCO BRL), and then analyzed on a 6% polyacrylamide-urea denaturing gel.

**Transient Transfections.** For the transient transfection assays, 6 × 10⁶ Ramos cells were cotransfected with 25 μg of a CD23b GAS wt or a CD23b GAS M2 firefly luciferase reporter plasmid and 25 μg of various expression plasmids (as indicated in the figure legend) by electroporation at 300 V and 960 Hz for 25 ms at 25°C. The transfectants were incubated with IL-4 (10 ng/ml) and IL-6 (100 U/ml) for 24 h. The transfected cells were then harvested, lysed, and assayed for luciferase activities with the Dual Luciferase Assay System (Promega) according to the manufacturer’s instructions. The firefly luciferase activity was normalized on the basis of renilla luciferase activity.

**Results**

**CD40 and IL-4 Synergistically Upregulate both CD23a and CD23b.** To identify and characterize the downstream effectors of the IL-4 signaling cascade, we focused our attention on CD23, a B cell activation molecule whose regulation displays lineage- and stage-specific features (41, 55). Although IL-4 and CD40 can individually induce modest levels of CD23, costimulation of human tonsilar B cells or purified centroblasts with both CD40 and IL-4 leads to a synergistic induction of surface CD23 expression (42, 43). We found that Ramos, an EBV-negative Burkitt’s lymphoma cell line extensively used to study the CD40 and/or IL-4 signaling pathways (56–59), mimics the physiological regulation of CD23 in normal B cells (data not shown). Since no study had previously explored the CD23 isoform(s) induced in response to CD40 or the CD40 and IL-4 combination, we performed RNase protection assays. As shown in Fig. 1, exposure of Ramos cells to either anti-CD40 Ab or IL-4 alone preferentially upregulated the CD23a isoform. A slight effect of IL-4 on the expression of CD23b could also be detected. Coculturing Ramos cells with both stimuli led to a strong induction of both CD23a and CD23b transcripts. Consistent with previous reports, constitutively high levels of both CD23a and CD23b were detected in an EBV-transformed B cell line (JY), whereas IL-4 stimulation of a monocytic cell line, U937, only upregulated the CD23b transcript (44, 48). β-actin levels were equivalent in all lanes (data not shown). Thus, costimulation with CD40 and IL-4 leads to a synergistic induction of both CD23 isoforms.

**Figure 1.** The synergistic upregulation of CD23 in response to CD40 and IL-4 reflects an induction of both CD23a and CD23b isoforms. Ramos cells were cultured for 24 h either in the absence of any stimulus or in the presence of an anti-CD40 Ab (0.1 μg/ml), an isotype-matched control Ab (0.1 μg/ml), human IL-4 (100 U/ml), a combination of anti-CD40 Ab plus IL-4, or a control Ab plus IL-4. U937 cells were either unstimulated or stimulated with IL-4. JY cells were left unstimulated. After harvesting the cells, total RNA was extracted and subjected to RNase protection analysis. The antisense riboprobe corresponds to a 600-bp 5′ EcoRI-HindIII fragment of the CD23a cDNA. The protected fragments of 588 and 488 nucleotides correspond to two isoforms of CD23a transcript which differ by one base change at position 96 in the 5′ untranslated region, while the 381-nucleotide protected fragment corresponds to the CD23b transcript (reference 44).
IRF-4 binds to the CD23b GAS. IL-4 stimulation has been shown to lead to the rapid binding of Stat6 to a functional element within the CD23b promoter termed the CD23b GAS (13, 45). However, our RNase protection assay studies had revealed only a minimal induction of CD23b in response to IL-4 alone. To determine whether additional factors could target the CD23b GAS and modulate Stat6 activity, we first performed EMSA experiments on Ramos cells stimulated with either IL-4, anti-CD40, or a control Ab. As shown in Fig. 2 A, Ramos cells contain multiple CD23b GAS binding complexes, most noticeably a broad constitutive (C1) and a slower mobility constitutive complex (C2). CD40 stimulation of Ramos cells led to a decrease in the intensity of the C1 complex (Fig. 2 A).

Stimulation of Ramos cells with IL-4 activates an additional superimposed complex that contains Stat6 (Fig. 2 C). In contrast to Ramos cells, the appearance of the CD23b GAS binding complexes in JY, an EBV-transformed B cell line expressing constitutively high levels of CD23b, was strikingly different. The C1 complex was absent, while the C2 complex became clearly visible (Fig. 2 A).

To dissect the CD23b GAS binding complexes, we then carried out EMSA experiments using a panel of mutated CD23b GAS elements as cold competitors of the radiolabeled CD23b GAS wt probe. Interestingly, a survey of the CD23b GAS had revealed that it contains two potential core sequences for IRF binding (GAAT and GAAA; Table I) (60). We thus mutated each of these two sites (M2 and...
Table I. Sequence Comparison between the Wt and M mutant CD23b GAS Oligonucleotides

| CD23b GAS wt | 5'-GGGTGAAATTCTAAGAAAAGGAC-3' |
| CD23b GAS M1 | 5'-GGGTGAAATTCTAAGGTGGGAC-3' |
| CD23b GAS M2 | 5'-GGGTGAAATTCTAAGAAAAGGAC-3' |
| CD23b GAS M3 | 5'-GGGTGAAATTCTAAGAAAAGGAC-3' |

Stat6 consensus 5' TNNNNNNNAA 3'
IRF response element core sequence 5' GAAA 3'
BCL-6 binding site 5' GAAAATTCTAAGAAAAGGAC 3'

M1, respectively) as well as a region between them (M3). These oligonucleotide competition experiments revealed that the C1 and C2 complexes displayed a differential pattern of competition (Fig. 2B). In particular, the CD23b GAS M2 mutant failed to compete with the C2 complex, suggesting that this complex targets the potential 5' IRF recognition sequence.

Previous studies have shown that purified BCL-6 can bind the CD23b GAS (22). Furthermore, expression of BCL-6 is downregulated by CD40 stimulation of B cells, and undetectable in EBV-transformed B cell lines (46, 61). These observations suggested that the C1 complex, which we had detected in Ramos but not in JY cells, might contain BCL-6. Indeed, incubation of nuclear extracts from Ramos cells with a BCL-6 antiserum, but not with a control antiserum, led to the disappearance of the C1 complex (Fig. 2C). These experiments also clearly revealed the presence of the C2 complex in both untreated and IL-4-treated cells. In IL-4-stimulated cells, an additional Stat6 complex could also be observed.

Our cold competition experiments suggested that binding of the C2 complex to the CD23b GAS requires the presence of a potential IRF binding site. To directly assess whether IRF-4 can physically interact with Stat6 by performing GST fusion protein binding assays (Fig. 3A, top). An association of Stat6 with IRF-4 could indeed be detected by incubating a GST–IRF-4 fusion protein with extracts from Ramos cells stimulated with anti-CD40, a control Ab, or human IL-4. No interaction of Stat6 with the GST moiety alone was observed. Furthermore, reprobing with anti-Stat3, anti-Stat1, anti-Stat2, and anti-Stat5 antisera revealed that none of these STATs were able to bind with IRF-4 (Fig. 3A, bottom, and data not shown). To confirm that the IRF-4–Stat6 interaction could occur in vivo, we used an anti–IRF-4 antiserum to immunoprecipitate extracts from Ramos cells stimulated with anti-CD40 Ab, a control Ab, or IL-4. Consistent with our previous observations, presence of the Stat6 protein could be detected in the IRF-4 immunoprecipitates from both stimulated and unstimulated Ramos lysates (Fig. 3B, top). Similar results were also observed in JY cells. Stripping and reprobing of the filter with an anti–IRF-4 Ab ensured for equal loading of the immunoprecipitates (Fig. 3B, bottom). Consistent with recent studies, which have detected IRF-4 in both the nuclear and cytoplasmic compartments (Riccardo Dalla-Favera, personal communication), the IRF-4–Stat6 association can occur in the absence of IL-4 stimulation. Interestingly, in both GST and coimmunoprecipitation experiments the IRF-4–Stat6 interaction appears to depend on the binding of IRF-4 to Stat6, IFN-gamma-inducible complex, IFN-stimulated gene factor 3 (ISGF3), which contains Stat1 and Stat2 as well as p48, a member of the IRF family (62). Since Stat6 and IRF-4 can bind to adjacent DNA elements, we then proceeded to test whether IRF-4–Stat6 interaction could occur independently of each other.

IRF-4 Physically Interacts with Stat6. Interactions between an IRF and STATs are critical for the formation of the IFN-α-inducible complex, IFN-stimulated gene factor 3 (ISGF3), which contains Stat1 and Stat2 as well as p48, a member of the IRF family (62). Since Stat6 and IRF-4 can bind to adjacent DNA elements, we then proceeded to test whether IRF-4–Stat6 interaction could occur independently of each other.

Thus, our data indicate that IRF-4 is capable of specifically interacting with Stat6 both in vitro and in vivo.
revealed that IRF-4 expression was upregulated in response to either CD40 or IL-4 stimulation (Fig. 4 A, top). A much stronger induction was noted when the anti-CD40 Ab was used in conjunction with IL-4. Consistent with previous reports (46, 61), CD40 stimulation of Ramos cells also led to the downregulation of BCL-6 (Fig. 4 A, middle). The same pattern of IRF-4 upregulation in response to CD40 and/or IL-4 was also detected in another EBV-negative Burkitt’s lymphoma cell line, BL-41 (data not shown), and by Western analysis, in human tonsillar cells (Fig. 4 B). Strong induction of IRF-4 was also observed in response to transfectants expressing CD40 ligand (CD40L) but not to control transfectants, indicating that IRF-4 expression is a physiological target of the CD40–CD40L interaction (59; data not shown). Kinetic studies showed that induction of IRF-4 is first noted at 2 h and can still be detected at 24 h (data not shown). No effect on IRF-4 expression was noted by culturing Ramos cells with either IFN-γ or IFN-α (data not shown). Reprobing of this Northern blot with a probe for ICSBP, an IRF family member closely related to IRF-4 (63), revealed that the CD40 and IL-4 signaling cascades do not upregulate ICSBP expression (data not shown). Consistent with previous reports (34), we also found that IRF-4 levels are highly increased in EBV-transformed B cell lines (data not shown). Thus, expression of IRF-4 in B cells is specifically targeted by the CD40 and IL-4 signaling cascades as well as by EBV transformation.

IRF-4 Interacts with the Kuppel Zinc Finger Transcriptional Repressor, BCL-6. The induction of IRF-4 expression by CD40 and IL-4 as well as by EBV suggested that IRF-4 might function as a transactivator of CD23 gene expression. However, we had detected constitutive binding of IRF-4 to the CD23b GAS in unstimulated Ramos cells, which only express low levels of CD23b. We then reasoned that, in this setting, IRF-4 function might be modulated by interaction with a repressor. Consistent with this hypothesis, our EMSA experiments had revealed binding of BCL-6 to the CD23b GAS in Ramos, but not in JY cells, which express high constitutive levels of CD23b. To assess whether IRF-4 could interact with BCL-6, we then performed UV cross-linking experiments with a bromodeoxyuridine-substituted CD23b GAS probe. This was followed by immunoprecipi-
tations with an IRF-4 antiserum, a BCL-6 antiserum, or a Stat6 antiserum as control (Fig. 5 A). The immunoprecipitates were then resolved by SDS-PAGE and Western blotted. Consistent with our EMSA results (Fig. 2), an ~62-kD protein was recognized by the IRF-4 antiserum. This corresponds to the molecular mass of IRF-4 plus the DNA probe. An additional cross-linked protein was also immunoprecipitated by the IRF-4 antiserum in Ramos, but not in JY cells. The size of this additional protein, after correction for the probe contribution, was ~90 kD, and was identical to that of the BCL-6 protein cross-linked to the CD23b GAS as determined by simultaneous immunoprecipitation with an anti-BCL-6 antiserum. Indeed, reprobing of the Western blot with an anti-BCL-6 antiserum confirmed that the p90 protein could be recognized by this antiserum (data not shown). Thus, the anti-IRF-4 antiserum can coprecipitate IRF-4 and BCL-6 bound to the CD23b GAS.

To determine whether interaction of IRF-4 and BCL-6 could occur independently of the presence of the CD23b GAS, we performed pull-down assays with a GST–IRF-4 fusion protein. As shown in Fig. 5 B, incubation of a GST–IRF-4 fusion protein with extracts from Ramos cells revealed a very strong association of IRF-4 with BCL-6. No interaction was observed with the GST moiety alone or upon incubation of the GST–IRF-4 with JY extracts, consistent with the lack of BCL-6 expression in EBV-transformed B cells. We also subjected extracts from Ramos cells cultured with or without IL-4 to immunoprecipitation assays with either an anti-IRF-4 or anti-BCL-6 antiserum (Fig. 5 C). This experiment demonstrated that IRF-4 and BCL-6 coimmunoprecipitated. Association of BCL-6 and IRF-4 was not affected by IL-4 treatment. Surprisingly, we did not detect increased levels of IRF-4 in our immunoprecipitations of IL-4- or CD40-treated extracts (Fig. 3 B and Fig. 5 C), despite an induction of IRF-4 levels by these stimulations (Fig. 4). We suspect that this may be due either to a limited ability of this antiserum to immunoprecipitate increasing amounts of IRF-4 or to the ability of IRF-4 upon IL-4-CD40 treatment to form alternative complexes that cannot be recognized by this antiserum.

To further corroborate the specificity of the association of IRF-4 with BCL-6 and Stat6, we also performed coimmunoprecipitation experiments with either an anti-IRF-4 or an antiserum against a nuclear factor κB (NF-κB) family member, p65. These assays were conducted on extracts from JY cells, which constitutively express p65 in the nucleus (49; Fig. 5 D). These experiments failed to detect an association of IRF-4 with p65.

**Figure 5.** IRF-4 interacts with BCL-6. (A) Ramos cells were either unstimulated or stimulated with IL-4 (100 U/ml). JY cells were unstimulated. Nuclear extracts were then prepared as described in the legend to Fig. 2, and incubated with a radiolabeled 5-bromodeoxyuridine-substituted CD23b GAS wt probe (BUDR-CD23b GAS wt) in a standard shift reaction. DNA–protein complexes were irradiated twice with 1,000 mJ of UV, and then immunoprecipitated (IP) with either an IRF-4, a BCL-6, or a Stat6 antiserum. The immunoprecipitates were resolved by 7% SDS-PAGE, transferred to a nitrocellulose membrane, and then exposed to an x-ray film. No cross-linking was detected in the absence of UV irradiation. (B) Ramos and JY cells were cultured as described in A. Nuclear extracts were then prepared and incubated with immobilized GST–IRF-4 fusion protein. Bound proteins were eluted, fractionated by 7% SDS-PAGE, transferred to a nitrocellulose membrane, and then probed with a BCL-6 antiserum. Binding to immobilized GST–IRF-4 fusion protein was detected by x-ray film (anti-BCL-6). (C) Ramos cells were either unstimulated or stimulated with IL-4 (100 U/ml). Nuclear extracts were prepared and immunoprecipitated with either an anti-IRF-4 or an anti-BCL-6 antiserum. The immune complexes were resolved by 7% SDS-PAGE, and then analyzed by Western blotting using an anti-BCL-6 antiserum (top). The blot was then stripped and reprobed with an anti-IRF-4 antiserum (bottom), as described in the legend to Fig. 3. (D) JY cells were unstimulated. Nuclear extracts were prepared and immunoprecipitated with either an anti-IRF-4 or an anti-p65 antiserum. The immune complexes were resolved by 7% SDS-PAGE, and then analyzed by Western blotting using an anti-p65 antiserum (top). The blot was then stripped and reprobed with an anti-IRF-4 antiserum (bottom), as described above.
These studies thus indicate that IRF-4 can interact with the Krüppel zinc finger transcriptional repressor, BCL-6, both in vitro and in vivo. Furthermore, no such interaction is detected in cells (JY) that express high levels of CD23b, suggesting that the presence of BCL-6 affects the functional ability of IRF-4 to modulate CD23b transcription.

The ability of IRF-4 to transactivate CD23b can be blocked by BCL-6. To directly assess whether IRF-4, in the absence of BCL-6, could function as a transactivator of CD23b, we performed transient transfection assays in U937 cells, a monocytic cell line that is capable of activating Stat6 in response to IL-4, but lacks both IRF-4 and BCL-6. Cotransfection of an IRF-4 expression vector with a luciferase reporter construct driven by an oligomerized CD23b GAS wt element resulted in a threefold induction in the luciferase activity, suggesting that IRF-4 can act as a transactivator of CD23b in the absence of Stat6 activation (Fig. 6 A). This level of induction was similar to that observed upon stimulation of U937 with IL-4. Interestingly, cotransfection of IRF-4 augmented, albeit not in a synergistic manner, the induction of the CD23b GAS wt reporter construct in response to IL-4. Consistent with the results of our EMSA experiments, a reporter construct driven by a mutant CD23b GAS element, which binds Stat6 but not IRF-4 (CD23b GAS M2, Fig. 2 B), displayed a normal IL-4 inducibility but could not be activated by IRF-4 cotransfection (Fig. 6 A). Furthermore, overexpression of IRF-4 was unable to enhance the IL-4-mediated activation of this CD23b GAS M2 reporter construct. Thus, these data suggest that optimal transactivation of CD23b requires the presence of both Stat6 and IRF-4.

Since BCL-6 is known to repress Stat6 function, we then proceeded to determine whether BCL-6 could block IRF-4 function. Indeed, cotransfection of BCL-6, but not of an empty vector, with IRF-4 was able to repress the ability of IRF-4 to induce the activity of the CD23b GAS reporter construct (Fig. 6 B). A similar inhibitory effect was also detected when BCL-6 was cotransfected with a reporter construct driven by the CD23b promoter in JY, an EBV-transformed B cell line, which constitutively expresses high levels of IRF-4 but no activated Stat6 (Fig. 6 C). These studies thus indicate that IRF-4 can transactivate the CD23b GAS and that BCL-6 can block IRF-4 function independently of its inhibitory effects on Stat6.

**Discussion**

IRF-4, a Lineage-Specific Effector of the IL-4 and CD40 Signaling Pathways. Biochemical and genetic studies have demonstrated that Stat6 plays a key role in IL-4 signaling (10). However, the rapid activation of Stat6 cannot solely account for the complex biological activities of IL-4 (1, 3). The IL-4 signaling pathway must thus use additional effector molecules. Our studies demonstrate that IRF-4 is both a target and a modulator of the IL-4 signaling pathway. This dual role of IRF-4 is thus reminiscent of that of IRF-1 in the IFN signaling cascade (26). In contrast to the IL-4 induction of Stat6, which has been detected in a wide variety of cells (13–17), IRF-4 expression is largely restricted to the lymphoid compartment (31, 32, 34). Thus, the recruitment of IRF-4 by the IL-4 signaling pathway provides a potential mechanism...
by which this cytokine can regulate the expression of target genes in a lineage-specific manner.

Similarly to IRF-1, whose induction is not restricted to the IFN pathway (64, 65), we found that the expression of IRF-4 in B cells can be independently upregulated by stimulation via the CD40 receptor. CD40 engagement is also known to lead to the rapid activation of the NF-kB/rel family of transcription factors (4). Although other IRFs have been shown to interact with NF-kB/rel proteins (66–68), we did not detect a physical interaction of IRF-4 with p65 (Fig. 5 D). However, this finding does not exclude that IRF-4 may be able to associate with other NF-kB family members and/or functionally modulate the activity of CD40-inducible NF-kB complexes. Such an interaction may allow IRF-4 to participate in the regulation of genes that are activated in response to CD40 alone.

Our studies indicate that costimulation of B cells with CD40 and IL-4 leads to maximal IRF-4 induction. This is accompanied by the simultaneous CD40-mediated downregulation of BCL-6 (Fig. 4 A), consistent with previous reports (46, 61). Since germinal center T cells have been shown to express CD40L as well as IL-4 (69), the transcriptional events triggered by activation of B cells with both stimuli are physiologically relevant. Thus, one may predict that B cells that have been successfully selected in the germinal center and have received appropriate T cell help should express high levels of IRF-4 in addition to low or absent BCL-6. In support of this notion, a small subpopulation of centrocytes with such a phenotype has been identified in close apposition to follicular dendritic cells. These cells have been postulated to represent “surviving centrocytes” (Riccardo Dalla-Favera, personal communication). The coordinated induction of IRF-4 and downregulation of BCL-6 may thus be an important step in the progression of B cells toward the terminal stages of differentiation.

Interplay between IRF-4, Stat6, and BCL-6. Our studies demonstrate that Stat6 and IRF-4 can physically interact. Preliminary experiments suggest that association of IRF-4 with Stat6 involves the COOH-terminal region of IRF-4. This portion of IRF-4 contains a putative α-helical region, which displays strong homology to the STAT-interacting domain of p48, the IRF component of the ISGF3 complex (63, 70). As in the case of the p48–Stat2 complex (71), tyrosine phosphorylation of Stat6 does not appear to be needed for its association with IRF-4. However, unlike the ISGF3 complex (70, 72), IRF-4 does not appear to be involved in recruiting Stat6 to the CD23b GAS. Our inability to detect a cooperative complex containing both IRF-4 and Stat6 also contrasts with the strong phosphorylation-dependent cooperative interaction between IRF-4 and the Ets protein, PU.1 (29, 35, 36).

Our transient transfection experiments indicate that IRF-4 can act as a transactivator and augment the Stat6 inducibility of CD23b. Our studies have revealed an additive rather than a synergistic interaction between IRF-4 and Stat6, suggesting that recapitulation of the synergistic induction of CD23b in vitro may require regions flanking the CD23b GAS and/or additional components. For example, studies of the IFN-β enhanceosome, a model system for transcriptional synergism, have demonstrated that this regulatory region (–110 to –53) contains multiple IRF-1 binding sites (73). Consistent with this notion, our survey of the CD23b promoter has revealed that the regions flanking the CD23b GAS may contain additional IRF-4 binding sites. Our inability to detect enhanced IRF-4 DNA binding in EMSAs upon IL-4 treatment (Fig. 2 A) may thus be due to the lack of these additional sites in the probes used. Although, in the CD23 system, IRF-4 acts as a positive regulator, IRF-4 contains multiple regions with transactivation and/or repressing potential (74–77). Therefore, the precise outcome of the Stat6–IRF-4 interaction is likely to be dictated by the specific arrangement of their DNA binding sites as well as by the presence of additional cofactors.

Indeed, our studies suggest that the function of IRF-4 can be profoundly affected by the presence of the Krüppel zinc finger transcriptional repressor, BCL-6 (19–21, 78, 79). BCL-6 is able to repress IRF-4 function in the absence of Stat6. This may allow BCL-6 to modulate the expression of Stat6-independent target genes. Indeed, we have found that BCL-6 binds to the IRF-4 binding site present in the Igκ 3’ enhancer (35, 36; data not shown). In contrast to the CD23b GAS, this DNA element does not bind Stat6. Thus, the BCL-6–IRF-4 interaction may underlie some of the defects exhibited by the BCL-6−/− deficient mice that are not corrected by the lack of Stat6 (24).

Various mechanisms may account for the repressive effects of BCL-6 on IRF-4 function. In addition to the known ability of BCL-6 to recruit the co-repressor machinery (80–83), BCL-6 may prevent high-affinity DNA binding by IRF-4 as suggested by our UV cross-linking experiments, which detected stronger CD23b GAS–IRF-4 complexes in the absence of BCL-6. Furthermore, previous studies have indicated that IRF-4 contains an inhibitory region (amino acids 207–300) that can mask its own transcriptional synergism with Stat6, BCL-6 and IRF-4, prolonged exposures of our
UV cross-linking experiments (Fig. 5 A) have revealed that the IRF-4 antiserum can immunoprecipitate, in addition to IR F-4 and BCL-6, a faint band of mobility identical to that of Stat6. Assembly of this complex may thus require specific three-dimensional contacts, which we are unable to fully reproduce with the techniques available to us. Alternatively, some of the interactions between Stat6, IRF-4, and BCL-6 could be mediated by additional cofactors. These findings thus lend support to the notion that assembly of these enhanceosome-like complexes may represent ideal targets for the final integration of signaling pathways (73). Furthermore, presence of lineage-specific components like IRF-4 and stage-specific repressors like BCL-6 within these complexes would endow cells with the ability to regulate gene expression in response to signals such as CD40 and IL-4 in a context-appropriate manner.

We thank Dr. Hirai for the anti–IRF-4 antiserum and Drs. Wang and Kikutani for the CD23 cDNA. We are very thankful to Dr. Dalla-Favera and members of his laboratory for providing us with cell lines and the IR F-4 and BCL-6 constructs. We are grateful to Yang Xu for her technical assistance. We also thank Drs. J. Siu and C. Schindler for reading this manuscript as well as for their constant support. We thank Drs. Dalla-Favera and Thanos for their critical reading of this manuscript.

This work was supported by the New York City Council Speaker’s Fund for Biomedical Research: Toward the Science of Patient Care, and a Grant-in-Aid from the American Heart Association.

Address correspondence to Alessandra Pernis. Department of Medicine, Columbia University, 630 West 168th St., New York, NY 10032. Phone: 212-305-3763; Fax: 212-305-4478; E-mail: abp1@columbia.edu

Submitted: 19 July 1999 Revised: 28 September 1999 Accepted: 1 October 1999

References

1. Brown, M., and J. Huri. 1997. Functions of IL-4 and control of its expression. Cyt. Res. Immunol. 17:31–32.
2. Chomarat, P., and J. Banchereau. 1997. An update on interleukin-4 and its receptor. Eur. J. Immunol. 27:833–844.
3. Paul, W.E. 1991. Interleukin-4: a prototypic immunoregulatory cytokine. Cell. 66:843–846.
4. Laman, J., E. Claassen, and R. Noelle. 1996. Functions of CD40 and its ligand, gp39 (CD40L). Crit. Rev. Immunol. 16:59–108.
5. Darnell, J., I. Kerr, and G. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1415–1420.
6. Ihle, J., and I. Kerr. 1995. Jak and Stats in signaling by the cytokine receptor superfAMILY. Trends Genet. 11:69–74.
7. Leonard, W.J., and J.J. O'Shea. 1998. JAKS and STATS: biological implications. Annu. Rev. Immunol. 16:293–322.
8. N elms, K., H. Huang, J. Ryan, A. Keegan, and W.E. Paul. 1998. Interleukin-4 receptor signaling mechanisms and their biological significance. Adv. Exp. Med. Biol. 452:37–43.
9. Kaplan, M., U. Schindler, S. Smiley, and M. Grusby. 1996. Stat6 is required for mediating responses to IL-4 and for development of TH2 cells. Immunity. 4:313–319.
10. Takeda, K., T. Tanaka, W. Shi, M. Matsumoto, M. Inami, S. Kashiwamura, K. Nakanishi, N. Yoshida, T. Kindimoto, and S. Akira. 1996. Essential role of Stat6 in IL-4 signaling. Nature. 380:627–630.
11. Shimoda, K., J. van Deursen, M.Y. Sangster, S.R. Sarawar, R.T. Carson, A. Tripp, C. Chu, F.W. Quelle, T. Nosaka, D.A. Vignali, et al. 1996. Lack of IL-4-induced TH2 response and IgE class switching in mice with disrupted Stat6 gene. Nature. 380:627–630.
12. Rouset, F., R. de Malefijt, B. Slierendregt, J.-P. Aubry, J.-Y. Bonnefoy, T. Defrance, J. Banchereau, and J. de Vries. 1988. Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt's lymphoma cell lines by human IL-4 and IFN-γ. J. Immunol. 140:2625–2632.
13. Kohler, I., and E. Rieber. 1993. Allergy-associated Ie and Fce receptor II (CD23b) genes activated via binding of an interleukin-4-induced transcription factor to a novel responsive element. Eur. J. Immunol. 23:3066–3071.
14. Schindler, C., H. Kashiwara, A. Pernis, R. Pine, and P. Rothman. 1994. STF-IL4: a novel IL-4 induced signal transducing factor. EMBO J. (Eur. Mol. Biol. Organ.) J. 13:1350–1356.
15. Moriggl, R., S. Berchtold, K. Friedrich, G.J. Standke, W. Kammer, M. Heim, M. Wissler, E. Stocklin, F. Guillaume, and B. Groner. 1997. Comparison of the transcriptional domains of Stat5 and Stat6 in lymphoid cells and mammary epithelial cells. Mol. Cell. Biol. 17:3663–3678.
16. Guo, F.H., K. Uetani, S.J. Haque, B.R. Williams, R.A. Dweik, F.B. Thunnissen, W. Cahan, and S.C. Erzurum. 1997. Interferon-γ and interleukin-4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. J. Clin. Invest. 100:829–838.
17. Gabay, C., B. Porter, D. Guenet, B. Billir, and W.P. Arned. 1999. Interleukin-4 (IL-4) and IL-13 enhance the effect of IL-1β on production of IL-1 receptor antagonist by human primary hepatocytes and hepatoma HepG2 cells. Differential effect on C-reactive protein production. Blood. 93:1299–1307.
18. Cattoretti, G., C.-C. Chang, K. Cechova, J. Zhang, B.H. Ye, B. Falini, D.C. Louie, K. Offit, R.S.K. Chaganti, and R. Dalla-Favera. 1995. BCL-6 protein is expressed in follicular center B cells. Blood. 86:111–117.
19. Chang, C., B. Ye, R. Chaganti, and R. Dalla-Favera. 1996. BCL-6, a POZ/Zinc-finger protein, is a sequence-specific transcriptional repressor. Proc. Natl. Acad. Sci. USA. 93:6947–6952.
20. Seyfert, V., D. Allman, Y. He, and L. Staudt. 1996. Transcriptional repression by the proto-oncogene BCL-6. Oncogene. 12:2331–2342.
21. Ye, B., F. Lista, F.L. Coco, D. Knowles, K. Offit, R. Chaganti, and R. Dalla-Favera. 1993. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science. 262:747–750.
22. Dent, A.L., A.L. Shaffer, X. Yu, D. Allman, and L.M. Staudt. 1997. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 276:589–592.
24. Dent, A., J. Hu-Li, W.E. Paul, and L.M. Staudt. 1998. T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6. Proc. Natl. Acad. Sci. U.S.A. 95:13823–13828.
25. Schindler, C., and J. Darnell. 1995. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Proc. Natl. Acad. Sci. U.S.A. 92:13823–13828.
26. Harada, H., T. Taniguchi, and N. Tanaka. 1998. The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie. 80:641–650.
27. Vaughan, P., A. van Wijnen, J. Stein, and G. Stein. 1997. Interferon regulatory factors: growth control and histone gene regulation—it's not just interferon anymore. J. Mol. Med. 75:348–359.
28. Taniguchi, T., N. Tanaka, and S. Taki. 1998. Regulation of interferon regulatory factors: growth control and histone gene regulation. Eur. J. Immunol. 28:368–378.
29. Eisenbeis, C., H. Singh, and U. Storb. 1995. Pip, a novel transcriptional activator. Cell 80:641–650.
30. Iida, S., P. Rao, M. Butler, P. Corradini, M. Boccadoro, B. Waard, C. Leung, M. Nouri-Shirazi, A. Orazi, R.S.K. Klemsz, S.R. McKercher, R.A. Maki, and M.L. Atchinson. 1992. PU.1 repression of the gene to 6p23-25.
31. Mittrucker, H., T. Matsuyama, A. Grossman, T. Kundig, J. Nicholl, A. Suzuki, S. Chung, L. Antonio, S. Suggs, G. Sutherland, D. Siderovski, and T. Mak. 1995. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). Nucleic Acids Res. 23:2127–2136.
32. Yamagata, T., J. Ishida, T. Tanaka, R. Sakai, K. Mitani, T. Taniguchi, Y. Yakazi, and H. Hirai. 1996. A novel interferon regulatory factor family transcription factor, IC SAT / Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol. Cell. Biol. 16:1283–1294.
33. Mittrucker, H., T. Matsuyama, A. Grossman, T. Kundig, J. Nicholl, A. Suzuki, S. Chung, L. Antonio, S. Suggs, G. Sutherland, D. Siderovski, and T. Mak. 1995. Cloning of human lymphocyte-specific interferon regulatory factor (hLSIRF/hIRF4) and mapping of the gene to 6p23-25. Genomics. 37:229–233.
34. Grossman, A., H. Mittrucker, J. Nicholl, A. Suzuki, S. Chung, L. Antonio, S. Suggs, G. Sutherland, D. Siderovski, and T. Mak. 1996. Cloning of human lymphocyte-specific interferon regulatory factor (hLSIRF/hIRF4) and mapping of the gene to 6p23-25. Genomics. 37:229–233.
35. Pongubala, J.M.R., S. Nagalapalli, M.J. Klemes, S.R. M. Cherker, R.A. Maki, and M.L. Atchinson. 1992. PU.1 recruits a second nuclear factor to a site important for globulin $k$ 3' enhancer activity. Mol. Cell. Biol. 12:368–378.
36. Pongubala, J.M.R., C.V. Beveren, S. Nagalapalli, M.J. Klemes, S.R. M. Cherker, R.A. Maki, and M.L. Atchinson. 1993. Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation. Science. 259:1622–1625.
37. Himmelmann, A., A. Riva, G.L. Wilson, B.P.L. C. Thevenin, and J.H. Kehrl. 1997. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood. 90:3984–3995.
38. Kikutani, H., and T. Kishimoto. 1990. Molecular genetics and biology of the low affinity IgE receptor (FceRII). Rev. Immunol. 141:249–258.
39. Conrad, D. 1990. FceRII/CD23: the low affinity receptor for IgE. Annu. Rev. Immunol. 8:623–645.
40. Richards, M., and D. Katz. 1991. Biology and chemistry of the low affinity IgE receptor (FceRII/CD23). Crit. Rev. Immunol. 11:65–86.
41. Bonnefoy, J.-Y., S. Lecoeur-Renolto, J.-P. Aubry, J.-F. Gauchat, and P. Graber. 1995. CD23 and B-cell activation. Curr. Opin. Immunol. 7:355–359.
42. Paterson, R., G. Lack, J.M. Domenico, G. Delepeasse, D.Y. Leung, T.H. Finkel, and E.W. Feland. 1996. Triggering through CD40 promotes interleukin-4-induced CD23 production and enhanced soluble CD23 release in atopic disease. Eur. J. Immunol. 26:1979–1984.
43. Choe, J.-H., S. Kim, R. Armitage, and Y.S. Choi. 1997. The functional role of B cell antigen receptor stimulation and IL-4 in the generation of human memory B cells from germinal center B cells. J. Immunol. 159:3757–3766.
44. Yokota, A., H. Kikutani, T. Tanaka, R. Sato, E. Barsumian, M. Suemura, and T. Kishimoto. 1988. Two species of human Fc receptor II (FceRII/CD23): tissue-specific and IL-4-specific regulation of gene expression. Cell 55:611–618.
45. Kotanides, H., and N.C. Reich. 1993. Requirement of tyrosine phosphorylation for rapid activation of a DNA binding factor by IL-4. Science. 262:1265–1267.
46. Allman, D., A. Jain, A. Dent, R. Male, T. Selvaggi, M. Kehry, and L. Staudt. 1996. BCL-6 expression during B-cell differentiation. Blood. 87:5257–5268.
47. Cleary, A.M., S. Fortune, M.J. Yellin, L. Chess, and S. Lederman. 1995. Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density bontarial B cells. J. Immunol. 155:3329–3337.
48. Wang, F., C. Gregory, C. Sample, M. Rowe, D. Liebowitz, M. Murray, A. Rickinson, and E. Kieff. 1990. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes. EBNA-A and LMP1 cooperatively induce CD23. J. Virol. 64:2309–2318.
49. Gupta, S., D. Xia, M. Jiang, S. Lee, and A. Pernis. 1998. Signaling pathways mediated by the TNF- and cytokine-receptor families target a common cis-element of the IRF-1 promoter. J. Immunol. 161:5997–6004.
50. Grumont, R., and S. Gerondakis. 1994. The subunit composition of NF-$k$B complexes changes during B-cell development. Cell Growth Differ. 5:1321–1331.
51. Frangioni, J.V., and B.G. Neel. 1993. Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. Anul. Biochem. 210:179–187.
52. Azam, M., C. Lee, I. Strehlow, and C. Schindler. 1997. Functionally distinct isoforms of STAT5 are generated by protein processing. Immunity. 6:691–701.
53. Berrier, A., G. Siu, and K. Calame. 1998. Transcription of a minimal promoter from the NF-$k$B gene is regulated by CRB/ATF and SP1 proteins in U937 promonocytic cells. J. Immunol. 161:2267–2275.
54. Thienes, C.P., L.D. Monte, S. Monticelli, M. Busslinger, H.J. Gould, and D. Vercelli. 1997. The transcription factor B cell-specific activator protein (BSAP) enhances both IL-4-
and CD40-mediated activation of the human \( \epsilon \) germline promoter. J. Immunol. 158:5874–5882.

55. Gordon, J. 1991. CD23: a novel multifunctional regulator of the immune system that binds IgE. Monogr. Allergy. 29:1–49.

56. Lederman, S., M. Yellin, A. Cleary, A. Pernis, G. Inghirami, L. Cohn, L. Covey, J. Lee, P. Rothman, and L. Chess. 1994. T-BAM/CD40-L on helper T lymphocytes augments lympho-kin induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. J. Immunol. 152:2163–2171.

57. Ning, Z., J. Norton, J. Li, and J. Murphy. 1996. Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signaling through CD40 and interleukin-4 receptor: role for inhibition of an early response gene, Berg36. Eur. J. Immunol. 26:2356–2363.

58. Lens, S., K. Tseles, B.F. de Drijver, M. van Oers, and R. van Lier. 1996. A dual role for both CD40-ligand and T NF-\( \alpha \) in controlling human B cell death. J. Immunol. 156:507–514.

59. Cheng, G., A. Cleary, Z. Ye, D. Hong, S. Lederman, and D. Baltimore. 1995. Involvement of CRAP1, a relative of TRAF, in CD40 signaling. Science. 267:1494–1498.

60. Escalante, C., J. Yie, D. Thang, A. Aggarwal. 1998. Structure of IRF-F-1 with bound DNA reveals determinants of interferon regulation. Nature. 391:103–106.

61. Cattoretti, G., C. Chang, K. Cechova, J. Zhang, B. Ye, B. Falini, G. Franzoso, L. Carlson, W. Biddison, U. Siebenlist, and J. Chebath. 1994. Induction by interferon-stimulated-gene factor 3 transcription complex. J. Biol. Chem. 270:9679–9683.

62. Darnell, J.E. 1997. STATs and gene regulation. Science. 276:2939–2945.

63. Brass, A., E. Kehrl, C. Eisenbeis, U. Storb, and H. Singh. 1996. PIP, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1. Mol. Cell. Biol. 16:6957–6964.

64. Fujita, T., L. Resis, N. Watanabe, Y. Kimura, T. Taniguchi, and J. Vilcek. 1989. Induction of the transcription factor IRF-1 and interferon-\( \beta \) mRNA by cytokines and activators of second-messenger pathways. Proc. Natl. Acad. Sci. USA. 86:9231–9235.

65. Harroch, S., M. Ravel, and J. Chebath. 1994. Induction by interferon and interleukin-6 of interferon regulatory factor-1 (IRF-1) gene expression in transfected human neuroblastoma cells. J. Biol. Chem. 273:10375–10380.

66. Darnell, J.E. 1997. STATs and gene regulation. Science. 276:1630–1635.

67. Neish, A.S., M.A. Read, D. Thanos, R. Pine, T. Collins. 1995. Interferon regulatory factor-1 physically interacts and synergistically induces major histocompatibility class I gene expression. J. Immunol. 155:1037–1045.

68. Neish, A.S., M.A. Read, D. Thanos, R. Pine, T. Collins. 1995. Endothelial interferon regulatory factor-2 cooperates with NF-\( \kappa \)B as a transcriptional activator of vascular cell adhesion molecule 1. Mol. Cell. Biol. 15:2558–2569.

69. Tsigelny, V.K., G. Inghirami, and J.J. Thorbecke. 1996. The physiology of germinal centers. Curr. Opin. Immunol. 16:381–421.

70. Horvath, C., G. Stark, I. Kerr, and J.J. Darnell. 1996. Interactions between STAT and non-STAT proteins in the interferon-stimulated gene factor 3 transcription complex. Mol. Cell. Biol. 16:6957–6964.

71. Martinez-Moczynbaker, M., M.J. Guthe, D.L. French, and N.C. Rech. 1997. Distinct STAT structure promotes interaction of STAT2 with the p48 subunit of the interferon-\( \alpha \)-stimulated transcription factor ISGF3. J. Biol. Chem. 272:20070–20076.

72. Qureshi, S.A., M. Salditt-Georgieff, and J.E. Darnell. 1995. Tyrosine-phosphorylated Stat1 and Stat2 plus a 48-kDa protein all contact DNA in forming interferon-stimulated-gene factor 3. Proc. Natl. Acad. Sci. USA. 92:3829–3833.

73. Thangos, D. 1996. Mechanisms of transcriptional synergism of eukaryotic genes. The interferon-beta paradigm. Hypertension. 27:1025–1029.

74. Rennkowitz, R. 1990. Transcriptional repression in eukaryotes. Trends Genet. 6:192–197.

75. Cowell, I. 1994. Repression versus activation in the control of gene transcription. Trends Biochem. 19:38–42.

76. Johnson, A. 1995. The price of repression. Cell. 81:655–658.

77. Herschbach, B., and A. Johnson. 1993. Transcriptional repression in eukaryotes. Ann. Rev. Cell Biol. 9:479–509.

78. Kawai, N., T. Miki, K. Ohashi, K. Suzuki, T. Fukuda, S. Hiroawa, and N. Aoki. 1994. Recognition DNA sequence of a novel putative transcription factor, BCL6. Biochem. Biophys. Res. Commun. 204:366–374.

79. Baran, B.W., R.R. Stanger, E. Hume, A. Sadhu, R. Mick, J.-P. Kerckaert, C. Deweindt, C. Bastard, G. Nucifora, N. Zeleznick-Le, and T. McKelthan. 1995. BCL6 encodes a sequence-specific DNA-binding protein. Genes Chromosomes Cancer. 13:221–224.

80. David, G., L. Alland, S.H. Hong, C.W. Wong, R.A. DePinho, and A. Dejean. 1998. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Proc. Natl. Acad. Sci. USA. 95:2549–2556.

81. Wong, C.W., and M.L. Privalsky. 1998. Components of the SMRT corepressor complex exhibit distinct interactions with the POZ domain oncoproteins PLZF, PLZF-RAR\( \alpha \) and BCL-6. J. Biol. Chem. 273:27695–27702.

82. Dhordain, P., O. Albagli, R.J. Lin, S. Anise, U. Quief, A. Leutz, J.P. Kerckaert, R.M. Evans, and D. Leprince. 1997. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ/ BCL6 oncoprotein. Proc. Natl. Acad. Sci. USA. 94:10762–10767.

83. Hung, K.D., and V.J. Bardwell. 1998. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. N. Biocen. 17:2473–2484.

84. Nagalupalli, S., and M.L. Atchinson. 1998. Transcription factor Pip enhance DNA binding by E47, leading to transcriptional synergy involving multiple protein domains. Mol. Cell. Biol. 18:4639–4650.

85. Keller, A.D., and T. Mamiya. 1991. Identification and characterization of a novel repressor of \( \beta \)-interferon gene expression. Genes Dev. 5:868–879.

86. Turner, C.A., Jr., D. Mack, and M.M. Davis. 1994. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell. 77:297–306.

87. Huang, S. 1994. Blimp-1 is the murine homolog of the human transcriptional repressor PR DI-BF. Cell. 78:9.

88. Collins, T., M. Read, A. Neish, M. Wightley, D. Thanos, and T. Mamiya. 1995. Transcriptional regulation of endothelial cell adhesion molecules NF-kB and cytokine-inducible enhancers. FASEB J. 9:899–909.